Pharmacological agents and natural compounds: available treatments for osteoporosis.
Study Goal
The researchers aimed to evaluate the potential of phytoestrogens and other natural compounds as safer alternatives to pharmacological treatments for osteoporosis.
Results Summary
The study suggests that phytoestrogens, along with other natural compounds, could provide a safer and effective alternative for osteoporosis treatment by influencing bone remodeling, osteoclastogenesis, and osteoblastogenesis. However, more high-quality clinical studies are needed to confirm these benefits.
Population
Not specified (general osteoporosis patients implied).
Effective Dosage
Not specified.
Duration
Not specified.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
bisphosphonates | decrease | osteoporosis | - | - | used for the treatment | #1 |
hormone therapy | decrease | osteoporosis | - | - | used for the treatment | #2 |
selective estrogen-receptor modulators | decrease | osteoporosis | - | - | used for the treatment | #3 |
calcitonin | decrease | osteoporosis | - | - | used for the treatment | #4 |
denosumab | decrease | osteoporosis | - | - | used for the treatment | #5 |
calcium and vitamin D supplementation | decrease | osteoporosis | - | - | used for the treatment | #6 |
teriparatide | decrease | osteoporosis | - | - | become available | #7 |
strontium ranelate | decrease | osteoporosis | - | - | become available | #8 |
romosozumab | decrease | osteoporosis | - | - | become available | #9 |
combination therapy of anabolic and anti-resorptive agents | decrease | osteoporosis | - | - | expected to be ideal | #10 |
phytoestrogens with estrogenic effects (e.g. genistein, daidzein, icariin, dioscin, Ginkgo biloba) | decrease | osteoporosis | - | - | could provide a safer alternative | #11 |
antioxidant and anti-inflammatory agents (e.g. acteoside, curcumin, resveratrol, Camellia sinensis) | decrease | osteoporosis | - | - | could provide a safer alternative | #12 |
treatments that exert their effects by multiple actions (e.g. kinsenoside, berberine, Olea europaea, Prunus domestica, Allium cepa) | decrease | osteoporosis | - | - | could provide a safer alternative | #13 |
Osteoporosis, a systemic skeletal disease characterized by a decrease in bone mass and deterioration of bone structure leading to an increased risk of fragility fractures, represents one of the major health problems worldwide. Currently, there are numerous pharmacological products used for the treatment of osteoporosis. Anti-resorptive drugs include bisphosphonates, hormone therapy, selective estrogen-receptor modulators, calcitonin, denosumab, calcium and vitamin D supplementation. Anabolic drugs such as teriparatide, strontium ranelate, romosozumab have recently become available based on advanced clinical trials. In recent years, combination therapy of anabolic and anti-resorptive agents is expected to be ideal anti-osteoporosis option. The adverse side effects caused by the long-term administration of pharmacological drugs have prompted researchers to study natural therapeutic compounds to find an alternative and effective way for osteoporosis treatment. Natural compounds including phytoestrogens with estrogenic effects (e.g. genistein, daidzein, icariin, dioscin, Ginkgo biloba), antioxidant and anti-inflammatory agents (e.g. acteoside, curcumin, resveratrol, Camellia sinensis), treatments that exert their effects by multiple actions (e.g. kinsenoside, berberine, Olea europaea, Prunus domestica, Allium cepa) could provide a safer alternative to primary pharmacological strategies. In this review, both pharmacological agents and natural compounds as available treatments for osteoporosis are characterized. In addition, possible mechanisms of action of all aforementioned treatments associated with bone remodelling, osteoclastogenesis, osteoblastogenesis, bone cell activity, death, and oxidative stress are presented. Nevertheless, more high-quality clinical studies with natural compounds are needed to provide greater evidence of the beneficial and safer antiosteoporotic application for the candidate.